Chugai To Deploy Chiome’s MAb Generation Technology
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Chugai Pharmaceutical signed a research agreement with a local Tokyo-based bio venture, Chiome Bioscience to deploy Chiome's Autonomously Diversifying Library system, a monoclonal antibody generation technology for developing monoclonal antibodies against various target proteins owned by Chugai, a Chugai spokesman confirmed Jan. 9
You may also be interested in...
Will 2009 Be The Year Of M&As For Japanese Drug Makers In Antibody Space?
The therapeutic market for monoclonal antibodies has grown exponentially since 2000, and Japanese pharmas, like counterparts in the U.S. and Europe, are looking to antibody drug development as a key-growth driver
Will 2009 Be The Year Of M&As For Japanese Drug Makers In Antibody Space?
The therapeutic market for monoclonal antibodies has grown exponentially since 2000, and Japanese pharmas, like counterparts in the U.S. and Europe, are looking to antibody drug development as a key-growth driver
Japan’s Chugai, Taisho To Seek Approval For Co-Developed Drug
Chugai Pharmaceutical and Taisho Pharmaceutical, both of Japan, plan to submit their eledecalcitol drug for approval in the country. Phase III trials of the vitamin D derivative have been positive, besting a Teijin competitor in comparison trials for treating fractures related to osteoporosis. Chugai, majority-owned by Roche, discovered the drug and is considering foreign trials, according to a spokesman. (Click here for more